Method of producing derivatives of 1.2-diaminocyclobutene-3.4-dion or chlorohydrates thereof

专利摘要:
Certain 1-(substituted amino)-2-(amino or substituted amino)cyclobutene-3,4-diones are potent histamine H2-antagonists useful in the treatment of peptic ulcers.
公开号:SU1375127A3
申请号:SU823458456
申请日:1982-05-17
公开日:1988-02-15
发明作者:Антонио Алджьери Альдо；Рей Креншо Ронни
申请人:Бристоль-Мейерз Компани (Фирма)；
IPC主号:

专利说明:

The invention relates to a process for the preparation of novel 1,2-diaminocyclobutene-3,4-dione derivatives of formula I
RI
A- (CH2) n, -Z- (CH2VNH
MR,
ABOUT
about
where R and R are each hydrogen or lower alkyl, or when hydrogen, R is allyl, propargyl or a group of the formula
J / -CH2: or
,
N
de m
P
Zat-vxw
O or 1;
2 or 3;
sulfur or oxygen;
formula group
B
: N -CH -5. or
ABOUT
", RSg
CHi-fTJ
,or
kz 25
.-ABOUT
RSK
R, R and RS
hydrogen or lower alkyl; methyl or together with the nitrogen atom form pyrrolidine-, methylpyrrolidine-, piperidine-, 1,2,3,6-tetrahydropyridyl-,
thirty
Example 2. 1-amino-2- | 2- - (5-dimethylaminomethyl-2-furyl) -methylthio ethylamino-1 cyclobutene-3,4-dione.
A solution of 2- (5-dimethylammonomethyl-2-furyl) methylthio-ethylamine (2.89 g, 13.5 mmol) in 30 ml of methanol is added dropwise over 30 minutes to ohhexamethylenimine-, heptamethylated to 5 ° C. a solution of 1,2-dime
or 3-aza bicyclo 3.2. 2 nano-group
or their chlorohydrates, which are histamine H-antagonists, which inhibit the secretion of gastric acid, and can therefore be used to treat ulcers of the digestive tract.
The aim of the invention is to develop a process for the preparation of new compounds of the formula I, which would possess valuable pharmacological properties.
The invention is illustrated by examples.
Example 1. 1-Amino-2- 3- (3- -piperidinomethylphenoxy) propylamino cyclobutene -3,4-dione.
A solution of 3- (3-piperidinemethylphenoxy) propylamine obtained from chlorohydrate (4.46 g, 13.9 mmol) in 40 m of methanol is added directly to a solution of 1,2-dimethoxycyclobutene-3,4-dione
-
13751272
(1.97 g, 13.9 mmol) in 40 ml of methanol, which is cooled to 5 ° C using a bath containing ice water. After standing for 2 hours at
at room temperature. the solution is cooled to 5 ° C and an excess of anhydrous ammonia is passed through it for 5 minutes. The reaction mixture was then stirred for 18 hours at room temperature and filtered, yielding 4.35 g of product.
The resulting product (4.20 g, 12.2 mmol) was suspended in 40 ml of a 95% aqueous solution of ethanol, and 6.11 ml (12.2 mmol) of an aqueous solution of 2.0N was added to the resulting solution with stirring. hydrochloric acid. The resulting solution is filtered, resulting in 4.33 g of the title compound as its hydrochloride. (mp. 254-257 ° C).
Calculated,%: C 60.90; H 6.90; N 11.06; C1 9.33.
,
Found,%: C 59.73; H 6.97;
 N 11.14; C1 9.36.
Example 2. 1-amino-2- | 2- - (5-dimethylaminomethyl-2-furyl) -methylthio ethylamino-1 cyclobutene-3,4-dione.
A solution of 2- (5-dimethylammonomethyl-2-furyl) methylthio ethylamine (2.89 g, 13.5 mmol) in 30 ml of methanol is added dropwise over 30 minutes to oh
toxiccyclobutene-3,4-dione (1.92 g, 13.5 mmol) with stirring. After 3 hours at room temperature, the solution is cooled to 5 ° C and an excess of anhydrous ammonia is passed through it for 5 minutes. The reaction mixture is stirred at room temperature for 18 hours, then filtered to obtain 2.48 g of the title compound, m.p. 227-230 C (with decomposition).
Samples for analysis are obtained by recrystallization from a 95% aqueous solution of ethanol and then from methanol, after which it is dried
in vacuo over 18 hours, / obtaining the title compound as a sticky, unsolvable solid.
The NMR spectrum (100 MHz) in deuterated (d-6) dimethyl sulfoxide shows about 0.2 mol of methanol.
Calculated,%: C 54.01; H 6.32; N 13.31; S 10.15.
, N, 0, S 0,2CH40
Found,%: C 53.72; H 6.07; N 14.01; S 10.51,
Example 3. 1-AMINO-2- | 2- (5-dimethylaminomethyl-2-thienyl) methylthio ethylamino | cyclo6utene-3,4-dione. - A solution of 2- (5-dimethylaminomethyl--2-thienyl) methylthio ethylamine (2.06 g, 8.94 mmol) in 20 ml of methanol is added immediately to cooling: a solution of 1,2-dimethoxycyclobutene-2, which is deposited at 5 ° C, 4-dione (1.27 g, 8.94 mmol) in 20 ml of methanol. After 3.3 hours at room temperature, the solution is cooled to 5 ° C and an excess of anhydrous ammonia is passed through it for 5 minutes. The reaction mixture is stirred for 18 hours at room temperature, then filtered, yielding 2.66 g of product. As a result of recrystallization from 95% aqueous ethanol, the desired compound is obtained, mp. 240-243 C (with decomposition).
Calculated,%: C, 51.67; H 5.88; N 12.91; S 19.70.
 N, 02.5 2.
Found,%: C 51.60; H 5.76; N 12.97; S 19.69.
Example 4. (5-Dimethyl-aminomethyl-2-furyl) methylthio | with ethyly-ji ..
but | -1-methylaminocyclobutene-3,4-dione.
A solution of 2- (5-dimethylaminomethyl--2-furyl) methylthio-ethylamine (2.89 g, 13.5 mmol) in 30 ml of methanol is added directly to a solution of 1,2-dimethoxycyclobutene-3, 4-diene cooled to 5 ° C. (1.92 g, 13.5 mmol) in 50 ml of methanol. The solution is stirred for 3 hours at room temperature, then cooled to 5 ° C. and an excess of anhydrous methyl amine is passed through it for 5 minutes. The reaction mixture is stirred for 18 hours at room temperature, the solvent is distilled off under reduced pressure, and the residue is triturated with acetonitrile, then filtered to obtain 2.9 g of crude product. This product is placed on 40 g of silica gel (230-400 mesh) and chromatographed by plate chromatography using a mixture of methanol and acetonitrile as a gradient eluant. The appropriate fractions are distilled off to dryness, combined in methanol solution, treated
activated carbon, filtered and methanol is almost dry. The solid was triturated with acetone ryl and filtered to give the title compound, so pl. 176-177.5 ° C.
Calculated,%: C 55.71; H 6.54; N 12.99; S 9.91. S.N ,, N, Oz5
Found,%: C 55.4; H 6.39; N 13.14; S 10.30.
Example 5. (5-Dimethyl amine nomethyl-2-thienyl) methylthio ethyl-1-methylaminocyclobutene-3,4-dione.
A solution of 2- (5-dimethylaminomethyl--2-thienyl) methylthio ethylamine (1.32 g of 5.73 mmol) in 20 ml of methanol is added to a solution of 1,2-dimethoxycyclobuten-3, 4-dione (814 mg, 5.73 mmol) in 15 ml of methanol. After holding the solution for 3.5 hours at room temperature, it is cooled to 5 ° C and an excess of anhydrous methylamine is passed through it for 5 minutes. The reaction mixture is stirred for 70 hours at room temperature, then filtered to obtain g of product. After recrystallization from ethanol, the desired compound is obtained, mp. 185-187 ° C.
Calculated,%: C 53.07; H 6.23; N 12.38; S 18.89. C, jH, N ,, 0, S
Found% C 53.18, H 6.21; N 12, 25; S 18.94.
Example 6. 1-Amino-2- 2- (5-dimethylphenyl, nome tyl-4-methyl-2-th e-nyl) - methylthio ethylamino-cyclobutene-3,4-dion.
A mixture of 2- (5-dimethylaminomethyl-4- -methyl-2-thienyl) methylthioJ ethylamine (3.0 g, 12.3 mmol) and 1 amino 2-methoxycyclobutene-3,4-dione (1.56 g , 12.3 mmol) in 50 ml of methanol is stirred at room temperature for 18 hours, then filtered and 3.72 g of product are obtained. After recrystallization from 95% aqueous ethanol, 3.1 g of the title compound are obtained.
The product obtained (3.1 g, 9.13 mmol) is suspended in 40 ml of methanol and 1.52 ml of an aqueous 6.0N hydrochloric acid solution is added to the suspension, while stirring. The reaction mixture is filtered and the solid is recrystallized
ten
15
methanol to give the title compound as a salt (chlorohydrate), m.p. 202-205 ° C.
Calculated,%: -C 47.93; H 5.90; N 11.18; S 17.06; C1 9.43.
C ,, H, N, .Hei
Found,%: C 47.74; H 5.79; N 11.41; S 17.21; C1 9.42.
Example 7. 1-Amino-2- 2- (5-β-piperidinome tyl-4-methyl-2-thie nyl) methylthioP ethylamino cyclobutene-3,4-dione.
The same operations as in Example 6 are repeated, except that 2- (5-dimethylaminomethyl-4-methyl-2- -thienyl) methylthio-ethylamine is replaced by an equimolar amount of 2- (5-pype -4-methyl-2-thienyl) methylthylamine. The product obtained (3.64 g, 9.6 mmol) is suspended in 50 ml of ethanol and 4.8 ml of aqueous solution is added to the resulting suspension. hydrochloric acid solution. The reaction mixture is filtered and the solid residue is recrystallized from aqueous ethanol, and the target compound is obtained as a salt (hydrochloride), mp. 150-157 C.
Calculated,%: C, 51.97; H 6.30; N 15.41; C1 8.52; S 10,10.
N
N
Ci "H2jN, 0,
Found (corrected for 1.58% of water),%: C 5.2.05; H 6.33; N 15.24; C1 8, 16; S 10.37.
Example 8. 1-AMINO-2- (3-pyperidinomethylphenoxy) propylamino cyclobuten-3,4-dione.
A solution of 3- (3-piperidinomethylphenoxy) propylamine, obtained from chlorhydrate (43.37 g, 0.135 mmol) in 250 ml of methanol is added to a suspension of 1-amino-2-methoxycyclobutene-3,4-dione ( 17.16 g, 0.135 mmol) in 350 ml of methanol and stirred at room temperature. After 22 hours, the reaction mixture was filtered, yielding 38.0 g of product.
50
The specified product (38.0 g, 0.111 mol) was suspended in 375 ml of aqueous 95% ethanol and 55.3 ml of aqueous 2.0N was added to the suspension with stirring. hydrochloric acid solution. The reaction mixture is filtered, thus obtaining 40.5 g of the desired compound as a salt (hydrochloride), which is identical to the product obtained according to the method described in Example 1.
13751276
This product is further purified; its solution in a 30% aqueous ethanol solution and the resulting solution are filtered through a filter filled with silica gel and activated carbon, the solvent is distilled off and the solid product is recrystallized from an aqueous solution of ethanol, to give the desired compound hydrochloride t. pl. 257-259 0.
Calculated,%: C 60.08; H 6.90; 11.0; C1 9.33.
C ,, Hj5N303-HCl
Found,%: C 59.82; H 7.10; 10.87; C1 9.47.
Example 9. 1-Amino-2- 3- (3-dimethylaminomethylphenoxy) propyl-2Q no1 cyclobutene-3,4-dione.
A mixture of 3- (3-dimesh1-aminomethylphenoxy) propylamine (1.41 g, 6.77 mmol) and 1-amino-2-methoxycyclobutene-3,4-dion (0.86 g 6, 77 mmol) in 40 ml methanol is stirred at room temperature for 20 hours, after which the reaction mixture is filtered, resulting in 1.95 g of the desired compound.
The resulting product (1.95 g, 6.43 mmol) is suspended in 35 ml of ethanol and 3.21 ml of 2.0N are added to the suspension with stirring. an aqueous solution of hydrochloric acid. The reaction mixture is filtered and the resulting solid residue is recrystallized from ethanol, resulting in the salt (hydrochloride) of the target compound, m.p. 205-207 S.
Calculated,%: C 56.55; H 6.52;
12.37; C1 10.43.
C, jH, N, 0, .HCl
Found,%: C 56.25; H 6.56;
12.36; C1 10.37.
Example 10. The procedure described in Example 9 is repeated, except that 3- (3-dimethylaminomethylphenoxy) propylamine is replaced with an equimolar amount:
a) 3- (3-pyrrolidinomethylphenoxy) - propylamine;
b) (2-methylpyrrolidino) methylphenoxy propylamine;
c) (3-methylpipolidino) methylphenoxy) propylamine;
(d) (4-methylpiperidino) methylphenoxy propylamine;
e) H- (W-morpholinomethylphenoxy) propylamine;
thirty
40
N
N
45
40
N
N
7P
f) 3-L3- (4-hydroxypiperidino) methylphenoxy propylamine;
g) (N-methylpiperazino) methylphenoxy propylamine:
h) 3-W- (1,2,3,6-tetrahydro-1-pyridyl) methylphenoxy propylamine;
i) 3- (3-hexamethyleneiminephenoxy) propylamine;
J) 3- (3-heptamethyleneyneminomethylphenoxy) propylamine;
k) 4- (3-piperidinomethylphenoxy) butylamine;
1) 5- (3-piperidine-methylphenoxy) - pentylamine;
m) 3- (3-octamethyleneiminomethylphenoxy) propylamine;
n) 3-3- {3-azabicyclo (3, 2. 2) non-3-wG methylphenoxy 1 propylamine;
0) 3- W- (3-pyrrolino) methylphenoxy propylamine
and, accordingly, receive;
a) 1-amino-2- 3- (3-pyrrolidinomethylphenoxy) -propylamino-cyclobutene-3,4-dione hydrochloride salt, m.p. 192.5-195 ° C.
Calcd.,%: C 59.10; H 6.61; N 11.49; C1 9.69.
C, gH, N, 0, -HCl
Found (including 0.55% water),%: C 58.92; H 6.63; N 11.61; C1 9.41;
b) 1-amino-2-3 hydrochloride salt of 3- (2-methylpyrrolidino) -propyl amino cyclobutene-3,4-dione, t, pl. 210-212 ° C
Calculated,%: C 60.08; H 6.90; N 11.06; C1 9.33.
, 0 ,. HC1
 Found,%: C 59.97; H 6.92; N 10.88; C1 9.46.
c) 1-Amino-2- 3- (3-methylpyrrolidino) methylphenoxy-propylaminocyclobutene-3,4-dione hydrochloride salt, m.p. 184.5-187 ° C.
Calculated,%: C 60.08; H 6; 90; N 11.06; C1 9.33. C ,, Hi5NjO ,, HCl
Found (including 0.26% water),%: C 60.43; H 7.02; N 11.03; C1 9.31;
d) 1-amino-2- | 3-C3- (4-methyl-piperidium o) methylphenoxoamino-cyclobuten-3,4-dione;
h) 1-amino-2- 3- 3- (1, 2, 3, 6-tetra hydro-1-pyridyl) methylphenoxy propyl but cyclobu ten-3, 4-dione, so pl. 213 215 С (with decomposition);
1) 1-amino-2- 3- (3-hexamethylene-iminemethylphenoxy) propylamino cyclo

0
five
0
five
ABOUT
0

-
five
278
ten-3,4-dione, hydrochloride salt, so pl. 200-202 ° C.
Calculated,%: C 60.98; H 7.16; N 10.67; C1 9.00.
CjoH N OyHCl
Found (including 0.28% water),%: C 61.25; H 7.14; N 10.55; C1 8.61;
J) 1-amino-2-W- (3-heptamethylene-iminemethylphenoxy) propylamino-3 cyclobutene-3,4-dione, melting point not determined, gradual decomposition at approximately 200-240 ° C,
Calculated,%: C 67.90; H 7.87; N 11, 31.
C ,, h ,, n, o,
Found,%: C 66.44; H 7.74; N 11.33;
t) 1-amino-2-p- (3-octamethylene-iminemethylphenoxy) propylamino-cyclo-butene-3,4-dione, melting point not determined.
Calculated,%: C 68.54; H 8.11; N 10.90.
C, H ,. N, 0
Found,%: C 68.42; H 8.42; N 11.10;
n) 1-amino-2-3- | 3- 3-azabicyclo- (3.2.2.) Non-3-yl methylphenoxy propyl-amino | cyclobutene-3,4-dione, hydrochloride salt, t. Pl. 162-164 ° C, Example 11. 1-Methylamino-2- (3-piPeridinomethylphenoxy-propylamino-cyclobutene-3,4-dione.
A solution of 3- (3-piperidinomethylphenoxy) propylamine (from dihydrochloride, 3.21 g, 10.0 mmol) in 40 ml of methanol was added to a solution of 1,2-dimethoxy-cyclobutene-3,4-dione (1.42 g, 10.0 mmol) in 40 ml of methanol. After
 about
incubated for 1 hour at 10 ° C and 30 minutes at room temperature, the solution is cooled to 5 ° C and then an excess of anhydrous methylamine is passed through it for 5 minutes. The mixture is stirred for 17 hours at room temperature, after which it is filtered and 2.77 g of product are obtained.
To the product (2.77 g), suspended in 40 ml of ethanol, 4.07 ml (8.1 mmol) of aqueous 2N HCl solution was added with stirring to obtain the hydrochloride salt of the target compound, m.p. 194-198 ° C.
Calculated,%: C 60.99; H 7.16; N 10.67.
.
Found (including 1.35% water),%: C 60.63; H 6.96; N 10.71.
91375127 10
Example 12. 2- 3- 3-Piperidi-a) 1-ethylamino-2- 3- (3-piperidinonomethylphenoxy (propylamino) -1-3-pi-methylphenoxy) propylamino cyclobutenridyl methylaminocyclobutene-3,4-dione.
Reproduce the general technique of j,. measure 11, except that the methylamine used in Example -11 was replaced with 1.08 g (10.0 mmol) of 3-aminomethylpyridine. The product is placed on silica gel (65 g, 230-400 mesh) and chromatographed using gradient elution with a mixture of methanol / methylene chloride containing 1% NH40H. The appropriate fractions are combined, combined, solid; 5 N 10.72; This residue is recrystallized from d) 2- | 3-3-piperidinomethylphenoxypropylamino) 2-propynyl amino cyclobutene-3,4-dione, m.p. 158-160 ° C.
Calculated,%: C 69.27; H 7.13; 20 N 11.02.
-3,4-dione;
b) 1-butylamino-2-f3- (3-piperidinindmethylphenoxy) propylamino 3-cycloben-3,4-dione;
c) 1-allylamino-2- 3- (3-piperidine-methylphenoxy) propylamino-cyclobut-3,4-dione, m.p. 158-159 ° C.
Calculated,%: C 68.90; H 7.62; N 10.96.
C.iiH ,, N, 0,
Found,%: C 68.81; H 7.70;
methanol and get the target compound, so pl. 174-178.6 pp.
CJ ,, N-jO,
Calculated,%: C H 6.96;
N 12.89.
CjyHjoN O, Found,%: C 69.26; H 7.25;
Found (including 1.35% water).,,%: N 10.78;
C 68.80; H 7.03; N 12.74. E) 1-benzylamino-2-3- (3-piperine Prymér 13. (3-Piperidi-25 dinomethylphenoxy) propylamino cyclomethylphenoxy) propylamino -1-propylbutotene-3,4-dione hydrochloric
aminocyclobuten-3,4-dione.
salt, so pl. 136-140 C.
Reproduce the general procedure of Example 11, except that the methylamine used in this example is replaced by 4.0 ml (48, .7 mmol) of propylamine. The product is placed on 60 g of silica gel (230-400 mesh) and chromatographed using gradient elution with a mixture of methanol and methylene chloride. The appropriate fractions are combined, the solid residue is recrystallized from methanol and the desired compound is obtained, m.p. 158-160 s.
Calculated,%: C 68.54; H 8.11; N 10.90.
,, N, 0,
Found,%: C 68.11; And 8.25; N 11.21.
Example) 14. Reproduce the general procedure of Example 12, except that instead of the 3-aminomethylpyridine used in this example, the following compound is used in excess molar amount:
a) ethylamine;
b) n-butylamine;
c) allylamine;
d) propargylamine;
e) benzylamine;
f) 6-methyl-3-aminomethylpyridine and get respectively:

methylphenoxy) propylamino cyclobutene N 10.72; d) 2- | 3-3-piperidine-methylphenoxy-3, 4-dione;
b) 1-butylamino-2-f3- (3-piperidinindmethylphenoxy) propylamino 3-cycloben-3,4-dione;
c) 1-allylamino-2- 3- (3-piperidine-methylphenoxy) propylamino-cyclobut-3,4-dione, m.p. 158-159 ° C.
Calculated,%: C 68.90; H 7.62; N 10.96.
C.iiH ,, N, 0,
Found,%: C 68.81; H 7.70;
CJ ,, N-jO,
Found%:
 butene-3,4-dione, hydrochloric
salt, so pl. 136-140 C.
Calculated,%: C, 66.44; H 6.86; N 8.94; C1 7.54.
Savne.
Found,%: C 65.41; H 7., 08; N 8.83; C1 7.67.
Example 15. 1-Amino-2- 3- (6- -Piperidinome of tyl-2-pyridyloxy) propylamine cyclobutene-3,4-dione.
A. 2-Chloro-6-piperidinomethylpyridine.
N-bromosuccinimide (g, 0.49 mol) and 1.0 g of benzoyl peroxide are added to a solution of 2-chloro-6-methylpyridine (50.0 g, 0.392 mol) in 393 ml of carbon tetrachloride. The mixture was stirred and heated under reflux for 22 hours, then cooled to 10 ° C and filtered. The cooled filtrate is then slowly treated with piperidine (83.5 g, 0.98 mol) and left under stirring at room temperature for 18 hours. After the pyridine hydrobromide has been removed by filtration, the filtrate is concentrated to approximately half the volume and extracted with 6 N. HCl (65 ml ) and 3 and. HC1 (40 ml). The acid extracts are alkalinized with 40% sodium hydroxide and the product is extracted with methylene chloride ohm. The solvent is evaporated, the residue is distilled and the desired compound is obtained (yield 41%) as
I
1375127 pl. YuT-YuZ S /
colorless oil, t./0.45 mm Hg, Art.
Calculated,%: C 62.71; H 7.18; N 13.29; C1 16.82.5
C ;, H, 5ClNi
Found,%: C 61.71; H 7.13; N 13.63; C1 17.20.
B. N-3- (6-Piperidinometid-2-pyridyloxy) propyl formamide.10
3-Aminopropanol (12.84 g, 0.171 mol) was added to a suspension of mineral oil with 50% sodium hydride (7.96 g, 0.166 mol) in 180 ml of dry DMF and the mixture was heated to BO- 5 83 ° C. A solution of 2-chloro-6-piperidino-methylpyridine (34.0 g, 0.161 mol) obtained in stage A in 180 ml of dry DMF is then added
12
eluting with a methylene methanol mixture containing 0.5. The desired compound is obtained in yellow oil (yield 63%).
D. 1-Amino-2- 3- (6-piperidyl thyl-2-pyridyloxy) propylamino-butene-3,4-dione.
A mixture of 3- (6-piperidinomethylridyloxy) prop1 | lamin (2.5 g, 10 mmol) obtained in a herd and 1-amino-2-methoxycyclobutene-dione (1.27 g, 10 mmol) in 35 methanol was stirred at room temperature After 18 hours, feed and get 2.71 g of the product.
The product (2.71 g, 7.87 mmol) is suspended in 35 ml of absolutized ethanol and with stirring
drops and at the end of the addition of that-20 water 6.0 n. HC1 solution
(7.87 mmol). Blend the mixture at 0 ° C, after which the salt is collected by filtration, recrystallized from aqueous ethanol to obtain the hydrogen salt of the desired salt, mp. 255-258 C.
Peratura is raised to 125-128 C for 3 hours, and then the mixture is kept at room temperature for 17 hours. The precipitated salts are removed by filtration and the solvent is evaporated off under vacuum. The oily residue is dissolved in chlorine: methylene chloride, washed with water, dried and the solvent is evaporated. The residue is again dissolved in acetonitrile and extracted with skelly B. After 30 removal of the solution; l crude oil is purified by chromatography on 270 g of silica gel (230-400 mesh) using gradient elution with a mixture of methanol, methylene chloride, evaporated, and the indicated product is obtained as a yellow oil, (21.63 g, 48 ,four%).
C. 3- (6-Piperidinomethyl-2-pyridyloxy) propylamine.
(7.87 mmol). The mixture was stirred for 64 hours at 0 ° C, after which the salt was collected by filtration, recrystallized from aqueous ethanol, and the hydrochloride salt of the title compound was obtained, m.p. 255-258 C.
Calculated,%: C 56.77; H 6.61; N 14.71; C1 9.31.
C, AN „N40, -NS1
Found,%: C 56.71; H 6.80; N 14.41; C1 9.98.
Example 16. 1-AMINO-2- 3- (6-dimethylaminomethyl-2-pyridyloxy) propylamino cyclobutene-3,4-dione.
The general procedure of Example 15 is repeated, except that the piperidine used in step A is replaced with an excess of anhydrous dimethylamine. Product (2.26 g, 7.43 mmol)
(6-Piperidinomethyl-2-pyridyl-Q is suspended in 40 ml of 95% ethanol
oxy) propyl 3-Formamide (19.6 g, 70.7 mmol) obtained in step B is added to a solution of 85% sodium hydroxide tablets (18.63 g
and, with stirring, add aqueous 2.0N. HC1 solution. After evaporation of the majority of the solvent, the residue is triturated in isopropyl alcohol.
eluting with methanol: methylene chloride containing 0.5%. The target compound is obtained as a yellow oil (yield 63%).
D. 1-Amino-2- 3- (6-piperidinomethyl-2-pyridyloxy) -propylamino-cyclobutene-3,4-dione.
A mixture of 3- (6-piperidinomethyl-2-pyridyloxy) prop-lamine (2.5 g, 10 mmol) obtained in Step C, and 1-amino-2-methoxycyclobutene 3, 4-dione (1.27 g, 10 mmol) in 35 ml of methanol is stirred at room temperature for 18 hours, filtered and 2.71 g of product is obtained.
The product (2.71 g, 7.87 mmol) is suspended in 35 ml of absolutized ethanol and with stirring added aqueous 6.0 n. HC1 solution
(7.87 mmol). The mixture was stirred for 64 hours at 0 ° C, after which the salt was collected by filtration, recrystallized from aqueous ethanol, and the hydrochloride salt of the title compound was obtained, m.p. 255-258 C.
Calculated,%: C 56.77; H 6.61; N 14.71; C1 9.31.
C, AN „N40, -NS1
Found,%: C 56.71; H 6.80; N 14.41; C1 9.98.
Example 16. 1-AMINO-2- 3- (6-dimethylaminomethyl-2-pyridyloxy) propyl amino cyclobutene-3,4-dione.
The general procedure of Example 15 is repeated, except that the piperidine used in step A is replaced with an excess of anhydrous dimethylamine. Product (2.26 g, 7.43 mmol)
suspended in 40 ml of 95% ethanol
and, with stirring, add aqueous 2.0N. HC1 solution. After evaporation of the majority of the solvent, the residue is triturated in isopropyl alcohol.
0.332 mol) in 180 ml of methanol and plant, 5 recrystallized from water
50
The thief is carefully boiled under reflux for 20 hours. The solvent is evaporated under vacuum and the residue is partially purified by re-dissolving in approximately 180 ml of a mixture of 20% methanol with methylene chloride and passing 38 g of silica gel through a layer. The silica gel is additionally washed with 120 ml of eluent and the combined filtrates are evaporated to an amber oil. The final purification was carried out by chromatography on 120 g of silica gel (230-400 mesh) using a gradient of ethanol to obtain the hydrochloride salt of the indicated compound, m.p. 230-234 C (with decomposition).
N
N
Calculated,%: C, 52.87; H 6.21; 16.44; C1 40.40.
C, 5H about "40z HC1
Found,%: C 51.52; H 5.98; 16.64; SG 10.88.
Example 17. 1-AMINO-2- 2- (3- -piperidinomethylthiophenoxy) ethylamino-HOJ cyclobutene-2,3-dione.
A. meta-Dithiobenzoyl.
A mixture of m-dithiobenzoic acid (20.8 g, 67.9 mmol) and thionylchloethanol yields the hydrochloride salt of the compound, m.p. 230-234 C (with decomposition).
0

N
N
Calculated,%: C, 52.87; H 6.21; 16.44; C1 40.40.
C, 5H about "40z HC1
Found,%: C 51.52; H 5.98; 16.64; SG 10.88.
Example 17. 1-AMINO-2- 2- (3- -piperidinomethylthiophenoxy) ethylamino-HOJ cyclobutene-2,3-dione.
A. meta-Dithiobenzoyl.
A mixture of meta-dithiobenzoic acid (20.8 g, 67.9 mmol) and thionyl-chloro1313
The reaction mixture (200 ml) is refluxed for 4 hours, filtered and the excess thionyl chloride is removed under vacuum.
B. Dithio-bis-3,3-N, N-di (piperidino) benzole-carbamide.
The crude product obtained in step A, dissolved in 100 ml of tetrahydrofuran, was added dropwise at 3 ° C to the solution, piperidine (25.1 g, 0.29 mol) in 500 ml of tetrahydrofuran. The mixture is stirred at room temperature for 76 hours and poured into 1500 ml of dilute HC1 (about 2 nD. After 1 hour, the product is extracted with ether and washed with water, aq. NaOH and water. The solvent is evaporated and 26.4 g of the above are obtained connections.
C.3- (Piperidinomethyl) thiophenol. To lithium aluminum hydride suspension
(45.3 g, 1.19 mol) in 2200 ml of sulfuric ether, a solution of dithio-bis-3,3-N, N-di (piperidino) benzolocarboxamide (141.5 g , 0.32 mol) obtained in Step B in 2200 ml of sulfuric ether and the mixture is stirred at room temperature for 20 hours. The mixture is decomposed by adding a saturated solution of sodium sulfate and filtered. The filter cake is stirred with 3000 ml of water and a solution of citric acid monohydrate (550 g, 2.62 mol) in 550 ml of water is added. The pH of the solution is adjusted to about 2 with 12 n. HC1 and then to pH8 with concentrated ammonium hydroxide. The solution is exhaustively extracted with sulfuric ether and 120 g of product are obtained.
An aliquot of this compound is recrystallized from isopropyl alcohol, m.p. 121-123 ° C;
Mass spectrum: 206 (M).
Calculated,%: C 69.56; H 8.21; N 6.76; S 15.46.
C, H, TNS
Found,%: C 69.02; H 8.03; N 6.67; S 15.06.
D. (Piperidinomethyl) thio-phenoxyl ethyl phthalimide.
A mixture of 3- (piperidinomethyl) thiophenol (2.07 g, 10 mmol), which was obtained at stage C, and N- (2-bromo-ethyl) phthalimide (2.41 g, 9.5 mmol) in Yu MP anhydrous DMF is stirred at

5 Q
with
five
0
2714
for 84 hours. The solvent is evaporated under reduced pressure and the crude oil is chromatographed on silica gel (100 g, 230-400 mesh) using a mixture of 2.5% methanol and methylene chloride as eluant. , 2%. The appropriate fractions are combined, evaporated and an oil is obtained, which crystallizes in sulfuric ether. Recrystallization from acetonitrile gives 1.2 g of the hydrobromic salt of the indicated compound, m.p. 180isTc.
Calculated,%: C 57.26; H 5.46; N 6.07; Br 17.32; S 6.95.
CjjHj N OiSHBr
Found,%: C 56.98; H.5.43; N 6.30; Br 17.51; S 7,10.
E.2- (3- Piperidinomethylthiophenoxy) ethylamine.
Anhydrous hydrazine (1.79 g, 56.0 mmol) is added to a suspension of the hydrobromic salt of C3- (pyperidinomethyl) thiophene and ethyl-3-phthalmine imide (5.17 g, 11.2 mmol) obtained in stage D in 200 ml 95% ethanol is stirred at room temperature for 18 hours and filtered. The filtrate is evaporated and the semi-solid remaining compound is mixed with several portions of the sulfuric ester. Evaporation of the solvent yielded 2.8 g of the title compound as a yellow oil.
F.1-amino-2- 2- (3-piperidinomethyl-thiophenoxy) ethylamino-cyclo-butene-3,4-dion.
The crude amine obtained in step E (1.4 g, 4.05 mmol) in 40 ml of methanol was added to a suspension of 1-amino -2 -2 methoxycyclobutene-3, 4-diad (0.515 g, 4.05 mmol) in 100 ml of methanol. The mixture is stirred for 20 hours at room temperature, filtered, and 0.8136 g of product is obtained. The second batch is obtained from the concentrated mother liquor and the combined batch is recrystallized from methanol to obtain 0.786 g (56%) of the desired compound, m.p. 228-230 ° С (with decomposition).
Calculated,%; C, 62.58; H 6.71; N 12.16; S 9,28.
Ci8H ,, N, OiS
Found,%: C 62,17; H 6.36; N 12.59; S 9.60.
1513
Example 18. 1-Amino-2- 3- (3- -piperidinomethylthiophenoxy) with a saw through the NOZ cycle of a 3-4, 4-dione.
A. (Piperidinomethyl) thiophenoxy propyl (LTalimide.
Reproduce the general procedure of step D of Example 17, except that an equimolar amount of L- (3-bromopropyl) phthalimide is used instead of N- (2-bromo-ethyl) phthalimium. The product treated by chromatography is recrystallized from isopropyl alcohol to obtain the hydrobromide salt of the indicated compound, i.e. Br. .
Calculated,%: C 58,10; H 5.72; N 5.89; Bg 16.81.
Found,%: C 57.79; H 5.41; N 5.73; Br 16.80.
B.З-СЗ-Piperidinomethylthiophenoxy) propSh1amin.
To the solution of the hydrobromic salt N- {3- 3- (piperidinomethyl) thiophenoxy propyl Dphthalimide (58.0 g, 0.12 mol) obtained in stage A, hydrazine hydrate (26.9 g, 0.54 mol and the reaction mixture is heated for 4.5 hours. The mixture is diluted with 500 ml of sulfuric ether, filtered, the filtrate is evaporated to a dry residue and the title compound is obtained as a colorless oil, mp 154-155 ° C / 0.15 mm Hg
Calculated,%: C 68.13; H 9.15; N 10.59.
Found,%: C 67.37; H 9.07; N 10.94.
C.1-AMINO-2- {j3- (3-piperidinomethylthiophenoxy) propylaminoJ cyclobutene-3,4-dione.
1-amino-2-methoxycyclobutene-3,4- -dione (1.20 g, 9.5 mmol) was added to a solution of the crude amine obtained in step B (2.50 g, 9.5 mmol) in 75 ml methanol and the mixture is stirred at room temperature for 16 hours. The precipitate is filtered and 2.82 g of crude product is obtained.
The crude solid compound (2.82 g, 7.84 mmol) is suspended in 30 ml of 95% ethanol and 4.0 ml of aqueous 2.0 N are added with stirring. rast thief HC1. After about 15 minutes, 40 ml of acetone is added and the mixture is left to stand at room temperature.
27
sixteen

0
five
0
five
0
five
0
within 16 hours. The precipitate is recrystallized from aqueous ethanol to obtain 1.64 g of the hydrochloride salt of the title compound, m.p. 236-237.5 ° C.
Calculated,%: C 57.64; H 6.52; N 10.61; S 8,10; C1 8.95.
С „Н„ Ы, 0,8 НС1
Found,%: C 57.72; H 6.56; N 10.66; S 8.49; C1 8.88.
Example 19. 1-Amino-2- 2- (5-dimethylaminomethyl-3-thienylmethyl-thio) ethylamino cyclobutene-3,4-dione.
A mixture of 2- (5-dimethylaminomethyl-3- -thienylmethylthio) ethylamine (2.11 g, 8.68 mmol) and 1-amino-2-methoxycycloboutene-3,4-dione (1.10 g, 8.68 mmol ) in the methane is stirred at room temperature for 18 h and filtered. By product, the product is recrystallized from 2-methoxyethanol to obtain 1.30 g of the title compound as a colorless solid, m.p. 234-236 ° C.
Calculated,%: C, 51.66; H 5.88; N 12.91; S 19.71.
C, 4
Found Z: C 51.53; H 5.64; N 12.62; S 19.91.
Example -20. 1-amino-2- 2- (5- -pipedinome tyl-3-nie nylmethio thio) -ethylamino cyclobutene-3,4-dione.
Reproduce the general procedure of Example 19, with the exception that equimolar amount of 2-5-piperidiomethyl-3-thienylmethylthio ethylamine is used instead of 2- (5-dimethylaminomethyl-3-thienylmethylthio) -ethylamine. The crude solid is recrystallized from 2-methoxy ethylene and gives the title compound (1.27 g), m.p. 236-238 C.
Calculated,%: C 55.86; H 6.34; N 11.50; S 17.54.
CnH NjOiS
Found,%: C 55.59; H 7.23; N 11.75; S t7.62.
Example 21. 1-Amino-2- 3- (5-dimethylaminomethyl-3-thienyloxy) propylamino Dicyclobutene-3,4-dione.
A mixture of equimolar amounts of (amine) propoxy -N, N-dimethyl-2-thiophenemethanamine and 1-amino-2-methoxycyclobuten-3,4-dione is reacted in accordance with the general procedure of Example 19 and get the target connection.
H-receptor histamine antagonists are effective inhibitors of digestive secretion in animals, including humans. A clinical study of such H-receptor histamine antagonist, such as cimetidine, has shown that it is an effective therapeutic agent in the treatment of peptic ulcers. Two standard model animal species intended for the study of the antisecretionary digestive activity of histamine Hj antagonists,
located in the center of the floor through which the catheter is passed. Thus, the rat's movements are not limited and it can move freely around the cage during the sampling period. Otherwise, the experiment is carried out in accordance with the known method.
Digestive secrets collected during the first hour after gastric lavage are discarded, as they may contain contaminants. In the oral method, the catheter is then removed from the cannula and the constipation is replaced by rats (gastric screw method. Animals are given oral oral caps) and dogs (Heidemhain's pocket test).
The ED-50 values for the compounds according to the invention obtained as a result of experiments on rats (gastric fistula method) and dogs (Heidemhain pocket test) are given in Table 1 and 2, respectively.
Determination of activity in relation to the suppression of digestive secretory activity in rats (gastric fistula method).
Males of Long Evans breed weighing 240–260 g each are implanted with cannulas (the type and method of implantation of a stainless cannula into the front wall of the stomach is fully consistent with the known ones)
After the operation, the animals are placed separately in cages with a solid bottom, on which sawdust is poured. Animals are supplied with food and water in an amount sufficient to sustain life throughout the preparatory period. Animals are used for experiments only after at least 15 days after the operation,
For 20 hours before using animals for experiments, they are deprived of food, but given water in an amount sufficient to maintain vitality. Immediately before sampling, the cannula is opened and the stomach is gently washed with 30-40 ml of warm saline saline or distilled water to remove residues of its contents. Then a catheter is inserted into the cannula instead of the locking screw and the rat is placed in a transparent rectangular plastic cage measuring 40x15 13 cm. At the bottom of the cage there is a slit about 1.5 cm wide and 25 cm long, passage 30
but water (2) by gastric intubation, after which they are returned to the cage for 45 minutes. After this time, the pore screw is removed and replaced with a catheter to which a small plastic bottle is attached to collect digestive secretions. Sample is taken within 2 hours (control.)
25, the catheter is then removed and replaced with a locking screw. Then the orally administered drug is administered in an amount of 2 ml / kg by gastric intubation. After 45 minutes, the locking screw is removed again, replaced with a catheter, to which a small plastic bottle is attached, and a sample is taken for another 2 hours. Samples of the second selection are compared with a control sample to determine the effectiveness of the investigational drug.
t
When the efficacy of the test compounds is determined with the parenteral route of administration, the test compound in an amount of 2 ml / kg is administered to the animals in the intratubular or subcutaneous route immediately after the first 60 minutes of sampling, which is discarded. t animals Intraperitoneally or subcutaneously test compound in an amount of 2 ml / kg. A sample is taken for a further 2 hours, compared with control samples, and the efficacy of the drug is determined.
Samples are centrifuged and placed in a measuring bowl about an ampoule to determine the volume. The titratable acidity is determined by titrating the sample (1 ml) to a pH value of 7 0.02 n, using sodium hydroxide solution using an automatic
40
45
50
located in the center of the floor through which the catheter passes. Thus, the rat's movements are not limited and it can move freely around the cage during the sampling period. Otherwise, the experiment is carried out in accordance with the known method.
Digestive secrets collected during the first hour after gastric lavage are discarded, as they may contain contaminants. In the oral method, the catheter is removed from the cannula and replaced with a locking screw. Animals are given oral peroral.
but water (2) by gastric intubation, after which they are returned to the cage for 45 minutes. After this time has elapsed, the locking screw is removed and replaced with a catheter to which a small plastic bottle is attached to collect digestive secretions. Sample is taken within 2 hours (control.)
whereupon the catheter is removed and replaced with a locking screw. Then the orally administered drug is administered in an amount of 2 ml / kg by gastric intubation. After 45 minutes, the locking screw is removed again, replaced with a catheter, to which a small plastic bottle is attached, and a sample is taken for another 2 hours. Samples of the second selection are compared with a control sample to determine the effectiveness of the investigational drug.
t
When the efficacy of the test compounds is determined with the parenteral route of administration, the test compound in an amount of 2 ml / kg is administered to the animals in the intratubular or subcutaneous route immediately after the first 60 minutes of sampling, which is discarded. t animals Intraperitoneally or subcutaneously test compound in an amount of 2 ml / kg. A sample is taken for a further 2 hours, compared with control samples, and the efficacy of the drug is determined.
Samples are centrifuged and placed in a measuring bowl about an ampoule to determine the volume. The titratable acidity is determined by titrating the sample (1 ml) to a pH value of 7 0.02 n, sodium hydroxide solution using an automatic
1913
burette and electro pH meter (Radiometer).
Results are obtained as percent inhibition relative to control data. Then, dose-response curves are obtained and the ED-50 values are calculated.
.
Using a regression analysis (for each dose value, at least three rats were used; to build the dose-effectiveness curve, the dose was studied in at least three different doses.
Determination of activity in relation to the research institute for the suppression of digestive secretory activity in dogs (test with the Heidenhein pocket).
Before the operation, hematological and chemical blood avalanches are carried out and the overall health of the selected female dogs is assessed. The dogs are vaccinated with Wax fabric 5 (Tissue Vax, DHLP-Pitman-Moore), placed in a common area and monitored for 4 weeks to detect possible diseases. 24 hours before the operation, the dogs are not given food, but they are supplied with water in sufficient quantity to maintain their vital activity.
Dogs are anesthetized with sodium pentothal (Abbott) (25-30 mg / kg intravenously). Subsequent anesthesia is performed using sifluran labels (Pitman Moore). A midsection along the white line of the abdomen provides a good view. The stomach is lifted into the operating area, stretched along the line of the greatest extent at several points and positioned along the selected incision line clamps. A pocket is made on the walls of the stomach, so that as a result it becomes possible to obtain genuine gastric juice. About 30% of the stomach walls (by volume) are resected. A cannula made from lightweight biologically inert material, such as nylon or derlin, is used. After surgery, antibiotics and analgesics are administered to dogs. The animals are left for 2-3 months for recovery.
The experiments were carried out as follows: dogs were not given food during the night (approximately 18 hours) before the experiment, water was given in the amount necessary to maintain vitality.
27
20
The dogs are then placed on the tie and a cannula is inserted into the vein for administration of drugs. As a base, histamine (100 µg / kg / h) and chlorphenylamine maleate (0.25 mg / kg / h) in an amount of 6 ml / h are continuously administered via a pump (injections (Harvard).
The administration continues for ~ 90 minutes, which allows a calm state of the dogs to reach, in which acid is released. At this moment, the test drug Yreparat or normal saline (in the case of control animals) together with the co-flower preparation in the amount of 0.5 ml / kg for 30 seconds are administered to the dogs. In the case when the experiments are carried out by oral administration of drugs, the drugs are administered via an artificial feeding tube in the amount of 5 ml / kg. The administration of the socogon drug continues; at the same time take samples of gastric juice after 15 min. In total, the experiment lasts 4.5 hours. Each sample is measured with an accuracy of 0.5 ml and the titratable acidity is determined as a result of the titration of the sample (1 ml) to a pH of 7.0 0.2 n. with a solution of sodium hydroxide (using an automatic burette and electr-meter).
Results are expressed as percent inhibition relative to control trials. Construct dose-response curves of efficacy and calculate ED-50 values using regression analysis. For the study of each dose, from 3 to 5 dogs are used, and at least three different doses are used to construct dose-response curves.
As can be seen from the data table. 1 and 2, the compounds obtained by the inventive method have a higher efficacy (25, 100 and up to 162 times) than cimetidine, and are of low toxicity.

权利要求:
Claims (1)
[1]
Invention Formula
The method of obtaining 1,2-β-diaminocyclobuten-3,4-dione derivatives of the formula I
I A- (CH5tV2: (
 five
where R and R are each hydrogen or lower alkyl, or. when R is hydrogen, R2 is allyl, propargyl, or Q is a group of the formula
CH 0 I-I 1I:
RI R
(f- 0
where R, and Rj have the indicated meanings, in methanol at a temperature of from 5 ° C to room temperature, followed by separation of the target product in the free form of rly as hydrochloride.

类似技术:

---

公开号 | 公开日 | 专利标题

---

SU1375127A3|1988-02-15|Method of producing derivatives of 1.2-diaminocyclobutene-3.4-dion or chlorohydrates thereof

---

DE69737980T2|2007-12-06|NITROSED AND NITROSYLATED ALPHA ADRENEORE RECEPTOR ANTAGONISTS, PREPARATIONS AND THEIR USES

---

KR960007524B1|1996-06-05|Substituted imidazolyl-alkyl-piperazine and diazepine derivatives for treating cerebrovascular disease

---

AU653160B2|1994-09-22|New sulphurous derivatives of imidazole, their preparation process, the new intermediates obtained, their use as medicaments and the pharmaceutical compositions containing them

---

EP0288973B1|1993-01-13|Benzothiazolinone derivatives, their production and pharmaceutical composition

---

SU1380614A3|1988-03-07|Method of producing derivatives of aryltriazoles or hydrochloride or hydrobromic salts thereof

---

US4254107A|1981-03-03|Long-lasting agonists of enkephalin

---

RU2184113C2|2002-06-27|Novel compounds

---

WO1999062892A1|1999-12-09|Aminoazole compounds

---

SU1241986A3|1986-06-30|Method of producing benzamide derivatives,hydrochlorides thereof or optical isomers

---

EP0008652B1|1982-09-22|New intermediates and their use for the preparation of new oxadiazolo-pyrimidine derivatives

---

DE2718707A1|1977-11-10|ISOTHIAZOLOPYRIDINE, THE PROCESS FOR THEIR MANUFACTURING AND MEDICINAL PREPARATIONS CONTAINING THESE COMPOUNDS

---

KR900004694B1|1990-07-02|Process for preparing a- aryl -a pyridyl alkanoic acid derivatives

---

EP0105131A1|1984-04-11|2-|- and 2-|-3-|-phthalimidines

---

SK278141B6|1996-02-07|Enolether amide 1,1-dioxo-6-chloro-4-hydroxy-2-methyl-n- -|-2h-thieno|1,2-thiazine-3-carboxylic acid, method of its production and pharmaceutical agent

---

KR860000103B1|1986-02-19|Process for preparing 3'-substituted-5'-|-1',2'4'-triazoles

---

DE60005368T2|2004-07-01|Thienopyran-carboxamide DERIVATIVES

---

JPH06135925A|1994-05-17|Intermediate for substituted 3,4-diamino-1,2,5-thiadiazole having activity of antagonizing histamine h2-receptor

---

FI102276B|1998-11-13|A process for the preparation of novel therapeutically useful 5-N, N-dialkylsulfoyl-1H-6,7,8,9-tetrahydro-1 H indole-2,3-dione 3-oximes

---

FI78107C|1989-06-12|Process for the preparation of antiulcerous thienoisothiazole-1,1-dioxide derivatives

---

KR100636515B1|2006-10-18|Novel type condensed pyridazinone compounds

---

US4772704A|1988-09-20|2,5-disubstituted-4|-pyrimidones having histamine H2 -receptor antagonist activity

---

SU1001855A3|1983-02-28|Process for preparing 2-substituted-1h-phenanthro|imidazo or their salts

---

DE3531504A1|1987-03-12|THERAPEUTICAL AGENTS CONTAINING 3-AMINOMETHYLPYRROL-1-YL-ALKYLAMINE AND THESE COMPOUNDS

---

DE2753391A1|1978-06-08|BENZISOTHIAZOLONE, METHOD FOR THE PRODUCTION THEREOF AND MEDICAL PREPARATIONS CONTAINING THESE COMPOUNDS

同族专利:

---

公开号 | 公开日

---

KR830009773A|1983-12-23|

---

JPH0478628B2|1992-12-11|

---

HUT38613A|1986-06-30|

---

NL189405C|1993-04-01|

---

IE53274B1|1988-09-28|

---

DE3218584A1|1982-12-23|

---

ATA197282A|1987-06-15|

---

DK159146B|1990-09-10|

---

DE3249715C2|1991-07-11|

---

FI78695C|1989-09-11|

---

MY8800118A|1988-12-31|

---

FR2513250B1|1986-03-07|

---

YU43077B|1989-02-28|

---

AT384805B|1988-01-11|

---

ES8306709A1|1983-06-01|

---

CH649527A5|1985-05-31|

---

YU212784A|1985-08-31|

---

FR2505835B1|1985-11-15|

---

US4390701A|1983-06-28|

---

KE3829A|1988-12-02|

---

GR75493B|1984-07-24|

---

ZA823328B|1983-03-30|

---

IE821169L|1982-11-18|

---

FI78695B|1989-05-31|

---

DE3218584C2|1989-11-02|

---

JPS57193427A|1982-11-27|

---

JPH0236159A|1990-02-06|

---

NO821586L|1982-11-19|

---

NO158419B|1988-05-30|

---

BE893236A|1982-11-18|

---

CA1190224A|1985-07-09|

---

CS244423B2|1986-07-17|

---

AU541843B2|1985-01-24|

---

HK83288A|1988-10-21|

---

SE457081B|1988-11-28|

---

ZW9782A1|1982-12-15|

---

ES512279A0|1983-06-01|

---

IT8248435D0|1982-05-17|

---

NO158419C|1988-09-07|

---

FI821698A0|1982-05-13|

---

HK84688A|1988-10-28|

---

DK219382A|1982-11-19|

---

FR2505835A1|1982-11-19|

---

DK159146C|1991-02-18|

---

PT74923B|1986-11-13|

---

OA07103A|1987-01-31|

---

CY1446A|1989-03-10|

---

NZ200586A|1985-09-13|

---

SE8203092L|1982-11-19|

---

FR2513250A1|1983-03-25|

---

AU8362082A|1982-11-25|

---

CH653989A5|1986-01-31|

---

LU84157A1|1983-04-13|

---

IT1210686B|1989-09-20|

---

YU104382A|1985-04-30|

---

GB2098988A|1982-12-01|

---

IL65803D0|1982-08-31|

---

GB2098988B|1985-07-24|

---

JPH0251425B2|1990-11-07|

---

DD202426A5|1983-09-14|

---

NL8201999A|1982-12-16|

---

SG38388G|1989-01-27|

---

KR880000968B1|1988-06-07|

---

PT74923A|1982-06-01|

---

IL65803A|1988-02-29|

---

HU194802B|1988-03-28|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US3346583A|1967-10-10|Disubstituted-a-phenethylamines |

---

GB1563090A|1975-07-31|1980-03-19|Smith Kline French Lab|Cyclobutene-diones|

---

GB1565966A|1976-08-04|1980-04-23|Allen & Hanburys Ltd|Aminoalkyl furan derivatives|

---

GB2001624B|1977-04-20|1982-03-03|Ici Ltd|Guanidine derivatives processes for their manufacture and pharmaceutical compositions containing them|

---

GB1604674A|1977-05-17|1981-12-16|Allen & Hanburys Ltd|Aminoalkyl-benzene derivatives|

---

GB1601459A|1977-05-17|1981-10-28|Allen & Hanburys Ltd|Aminoalkyl thiophene derivatives|

---

GB2023133B|1978-04-26|1982-09-08|Glaxo Group Ltd|Heterocyclic derivatives|

---

EP0006679B1|1978-05-24|1982-07-21|Imperial Chemical Industries Plc|Antisecretory thiadiazole derivatives, processes for their manufacture and pharmaceutical compositions containing them|

---

US4242351A|1979-05-07|1980-12-30|Imperial Chemical Industries Limited|Antisecretory oxadiazoles and pharmaceutical compositions containing them|AR228941A1|1978-04-26|1983-05-13|Glaxo Group Ltd|PROCEDURE FOR PREPARING NEW DERIVATIVES OF 3,5-DIAMINO-1,2,4-TRIAZOLE WHICH ARE ACTIVE AGAINST HISTAMINIC RECEPTORS|

---

US4788184A|1981-05-18|1988-11-29|Bristol-Myers Company|Substituted 3-cyclobutene-1,2-diones as anti-ulcer agents|

---

US4847264A|1982-07-21|1989-07-11|Rorer Pharmaceutical Corporation|Bicyclic nitrogen heterocyclic ethers and thioethers, and their pharmaceutical uses|

---

AU1956283A|1982-10-02|1984-04-05|Smith Kline & French Laboratories Limited|1-pyrid-2-yl-oxy)-prop-1-yl- amino) - 2-aminocyclobut-i-ene-3,4-diones|

---

AU2222083A|1982-12-14|1984-06-21|Smith Kline & French Laboratories Limited|Pyridine derivatives|

---

US4588719A|1984-04-27|1986-05-13|William H. Rorer, Inc.|Bicyclic benzenoid aminoalkylene ethers and thioethers, pharmaceutical compositions and use|

---

DE3326545A1|1983-07-22|1985-01-31|Ludwig Heumann & Co GmbH, 8500 Nürnberg|PROPAN-2-OL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS|

---

DE3404786A1|1984-02-10|1985-08-14|Ludwig Heumann & Co GmbH, 8500 Nürnberg|NEW ALKANOL DERIVATIVES, METHOD FOR THEIR PRODUCTION AND MEDICINAL PRODUCT CONTAINING THESE COMPOUNDS|

---

DE3408327A1|1984-03-07|1985-09-12|Ludwig Heumann & Co GmbH, 8500 Nürnberg|DIAMOND DERIVATIVES, METHOD FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS|

---

JPH058183B2|1984-06-01|1993-02-01|Ikeda Mohando Co|

---

FR2571723B1|1984-10-12|1988-08-26|Lipha|THIENO AND FURO-PYRROLES DERIVATIVES, METHODS OF PREPARATION AND MEDICAMENTS CONTAINING THEM|

---

US4598067A|1984-10-16|1986-07-01|Biomeasure, Inc.|Antiulcer compounds|

---

US4785003A|1984-10-16|1988-11-15|Biomeasure, Inc.|N-disubstituted glycine and B-amino-propionic acid derivatives having anti-ulcer activity|

---

US4595757A|1984-12-13|1986-06-17|American Home Products Corporation|N-alkylated benzo- and hetero-fused antisecretory agents|

---

EP0226653B1|1985-12-20|1989-02-22|LITEF GmbH|Method to determine heading by using and automatically calibrating a 3-axis magnetometer rigidly fitted in an aircraft|

---

US4927970A|1987-05-14|1990-05-22|Bristol-Myers Company|Substituted 3-cyclobutene-1,2-dione intermediates|

---

US4927968A|1987-05-14|1990-05-22|Bristol-Myers Company|Chemical intermediates and process|

---

US5112866A|1988-09-06|1992-05-12|Ortho Pharmaceutical Corporation|Ethanesulfonamide derivatives|

---

US5168103A|1991-01-22|1992-12-01|American Home Products Corporation|[[2- amino]alkyl]-acid derivatives|

---

WO1994020489A1|1993-03-09|1994-09-15|Sankyo Company, Limited|Thienyloxybutenyl derivative|

---

US5506252A|1993-11-17|1996-04-09|American Home Products Corporation|Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones|

---

US5354763A|1993-11-17|1994-10-11|American Home Products Corporation|Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones|

---

US5466712A|1994-11-04|1995-11-14|American Home Products Corporation|Substituted n-aryl-1,2-diaminocyclobutene-3,4-diones|

---

US5464867A|1994-11-16|1995-11-07|American Home Products Corporation|Diaminocyclobutene-3,4-diones|

---

US5872139A|1996-06-17|1999-02-16|American Home Products Corporation|Heterocyclymethylamino derivatives of cyclobutene-3,4-diones|

---

US5750574A|1996-07-17|1998-05-12|American Home Products Corporation|Fluorinated N-arylmethylamino derivatives of cyclobutene-3,4-diones|

---

US5780505A|1996-07-17|1998-07-14|American Home Products Corporation|Substituted N-arylmethylamino derivatives of cyclobutene-3, 4-diones|

---

US5846999A|1996-07-17|1998-12-08|American Home Products Corporation|Substituted N-arylmethylamino derivatives of cyclobutene-3,4-diones|

---

US5763474A|1996-07-17|1998-06-09|American Home Products Corporation|Substituted N-arylmethylamino derivatives of cyclobutene-3,4-diones|

---

US5840764A|1997-01-30|1998-11-24|American Home Products Corporation|Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones|

---

US6376555B1|1998-12-04|2002-04-23|American Home Products Corporation|4-substituted-3-substituted-amino-cyclobut-3-ene-1,2-diones and analogs thereof as novel potassium channel openers|

---

TW200514775A|2003-10-22|2005-05-01|Wyeth Corp|Methods for the preparation of {2-[-dioxo-2,6-diaza-bicyclo[5.2.0]-non-1-en-2-yl]ethyl} phosphonic acid and esters thereof|

---

CN103242210B|2012-02-09|2014-09-24|北京艾百诺科技有限公司|Mulin acetate containing substituted squaric acid and application thereof|

---

WO2022034121A1|2020-08-11|2022-02-17|Université De Strasbourg|H2 blockers targeting liver macrophages for the prevention and treatment of liver disease and cancer|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

US06/264,533|US4390701A|1981-05-18|1981-05-18|1-Amino-2-[3-propylamino]cyclobutene-3,4-dione|

---